Barrett Elizabeth A. 4

4 · Allogene Therapeutics, Inc. · Filed Jun 23, 2026

AI-generated summary of this filing

Updated Jun 23, 2026

Allogene (ALLO) Director Elizabeth Barrett Receives RSU Award

What Happened

Elizabeth A. Barrett, a director of Allogene Therapeutics (ALLO), was granted 95,400 restricted stock units (RSUs) on 2026-06-18. The RSUs were awarded at $0.00 (no cash paid) and are recorded as a derivative award (code A) — total immediate cash value reported = $0.00. Each RSU represents a contingent right to one share of common stock upon vesting.

Key Details

Transaction date and price: 2026-06-18; grant price $0.00 per RSU (award).
Quantity: 95,400 RSUs granted.
Shares owned after transaction: Not specified in the provided filing.
Vesting and deferral (footnote): RSUs vest in two equal semi-annual installments over the one‑year period from the grant date. The reporting person elected to defer receipt of shares upon vesting under the company’s Non‑Employee Director Compensation Policy until the earlier of (i) 30 days after separation from service or (ii) a change in control.
Filing timeliness: Form 4 was filed 2026-06-23 for a 2026-06-18 transaction (appears to be filed after the standard 2-business‑day reporting window).

Context

RSU grants are a common form of director compensation and are treated as derivative awards until they vest into actual shares; they are not an open‑market purchase or sale. Such awards do not necessarily signal immediate buying or selling intent by the insider. The deferral election means shares may not be delivered to the director at vesting and could be delayed until separation or a change in control.

Form 4

Period: 2026-06-18

Director

Transactions

Award
Restricted Stock Unit
[F1]
2026-06-18+95,400→ 95,400 total
→ Common Stock (95,400 underlying)

Footnotes (1)

[F1]Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.

Signature

/s/Earl Douglas, Attorney-in-Fact|2026-06-23

1 file